Health & Biotech
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
Health & Biotech
Creso Pharma posts record of near $9 million of revenue in FY22 as its blazing M&A trail pays back
Health & Biotech
EZZ delivers spectacular success in China, pays dividends, eyes expansion into Southeast Asia
Health & Biotech
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
Health & Biotech
Wellnex is a health and wellness darling as financials strengthen
Health & Biotech
Which ASX stocks are on the path from FDA to clinical trial in 2023?
Health & Biotech
Creso subsidiary Mernova Medicinal expands further into Canada, secures largest purchase order
Health & Biotech
Osteopore acquires multiple medical distribution businesses, closing in on cash flow positive
Health & Biotech
ASX Health Stocks: UBI jumps 10pc on Xprecia Prime study; Neuren gets another green light from FDA
Health & Biotech
ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow
Health & Biotech
PharmAust’s MND trial progresses to elevated MPL doses
Health & Biotech
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.